500mg film coated tablets
Each tablet contains Metformin HCl 500mg as the active ingredient.
1. Diet-failed, maturity onset diabetics, especially if over-weight
(A) Alone as initial therapy
(B) Combination therapy with a suphonylurea
2. Adjuvant therapy in insulin-dependent diabetics, especially if overweight.
A reduction of diabetics complications has been shown in overweight type2 diabetic patients treated with Metformin as fist line therapy after diet failure.
Dosage and administration
Usual starting dose is 1 tablet 500mg 2 or 3 times given during or after meals.
After 10 to 15 days the dose should be adjusted on the basis of blood glucose measurements.
A slow increased dose may improve gastro intestinal tolerability.
Normal dosage range
1.5g (1 tab 500mg x 3) a day is often sufficient to obtain diabetic control.
The dose can be increased up to 3g daily.
It important that Juformin tablets should be taken in divided doses with meals. Control may be attained within a few days, but occasionally requires up to ten weeks. Once control has been obtained, it may be possible to reduce the dosage.
Diabetic coma and ketroacidosis. As with all drugs primarily excreted by the kidney, seriously impaired renal function, chronic liver disease, cardiac failure, myocardial infarction, alcoholism, chronic or acute disease states associated with tissue hypoxia.
Care is advised in cases of renal insufficiency. The use Juformin is not advised in pregnancy, although clinical investigation has revealed no evidence of any teratogenic effect; where decompensation has occurred temporarily as a result of infection, trauma, operation etc conditions that may cause dehydration.
Because of the possibility of hypoglycaemia in combination therapy with a suphonylurea or insulin, diabetic control should be monitored by blood sugar readings.
Recent work has indicated the possibility of an interaction between metformin and certain anticoagulants. Some adjustment of anticoagulant dosage may, therefore, be necessary.
Hypoglycemia has not been seen with metformin doses of up to 85g.
Juformin is well tolerated with only minor, usually transient, gastro-intestinal upsets. These can generally be avoided by taking Juformin with meals, or occasionally by a temporary lowering of the dose. Only in about 3 percent of patients, it is necessary to withdraw Juformin therapy, and it is therefore, important that the treatment is not abandoned at the first sign of intolerance. Usually these upsets have disappeared by the time diabetes is controlled and do not return.
Does not lower blood sugar in non-diabetics and in diabetics does not cause hypoglyceamia when used alone. (In combination therapy, please see precautions).
Reduces overweight. Lower levels of plasma insulin, cholesterol. triglycerides and pre-B-lipoproteins. Improves glucose assimilation. The few cases of lactic acidosis that have been reported occurred when the use of metformin was contra-indicated.
Patients should be periodically reassessed to ensure the absence of conditions predisposing to lactic acidosis especially in those patients over 60 years of age. Patients should be instructed to discontinue metformin therapy if there is sudden onset of nausea, vomiting, diarrhoea, hyperventilation, deep and rapid breathing, malaise, confusion, abdominal pains and loss of consciousness.
Juformin is supplied as 500mg tablets in blister pack of 100 as well as tamper proof jars of 100 tablets.
Avoid exposure to sunlight, heat and moisture.
Keep this medicine out of the reach of all children.
JUHEL NIGERIA LIMITED
35 Nkwubor Road, Emene,